US2020246508A1PendingUtilityA1
Natural tissue scaffolds as tissue fillers
Est. expiryJul 28, 2031(~5 yrs left)· nominal 20-yr term from priority
A61L 27/362A61L 27/3633A61L 27/505A61L 2430/00A61L 2300/206A61L 2300/41C08L 5/08A61L 2300/236A61L 2300/252A61L 2300/104A61L 27/54A61L 27/227A61K 38/18A61K 31/728A61L 27/20A61P 31/04A61K 38/1709A61L 27/3604A61L 27/3683A61P 29/00A61L 27/34
72
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Tissue fillers derived from decellularized tissues are provided. The tissue fillers can include acellular tissue matrices that have reduced inflammatory responses when implanted in a body. Also provided are methods of making and therapeutic uses for the tissue fillers.
Claims
exact text as granted — not AI-modified1 . A tissue filler, comprising:
an acellular tissue matrix having the ability to maintain the same shape, size, and sponge property after being implanted for one week as was observed prior to application to a tissue site; and exogenous hyaluronic acid (HA) on a surface of the acellular tissue matrix at a concentration that reduces an inflammatory response or fibrosis when the tissue filler is applied to the tissue site as compared to the same tissue filler not comprising hyaluronic acid.
2 . The tissue filler of claim 1 , wherein a concentration of HA on the acellular tissue matrix is between approximately 0.5 mg and approximately 5.0 mg per gram of tissue filler.
3 . The tissue filler of claim 1 , further comprising at least one growth factor.
4 . The tissue filler of claim 3 , wherein the at least one growth factor is selected from at least one of FGF, VEGF, PDGF, Angiopoitin-2, or Follistatin.
5 . The tissue filler of claim 1 , wherein the tissue filler has been treated to reduce a bioburden.
6 . The tissue filler of claim 1 , further comprising an antimicrobial agent.
7 . The tissue filler of claim 6 , wherein the antimicrobial agent includes at least one of chlorhexidine (CHX) and silver.
8 . The tissue filler of claim 7 , wherein the CHX has a concentration between approximately 0.1 mg and approximately 3.0 mg per gram of tissue filler.
9 . The tissue filler of claim 7 , wherein the silver has a concentration between approximately 0.1 mg and approximately 1.0 mg per gram of tissue filler.
10 . The tissue filler of claim 1 , wherein the tissue filler is capable of being compressed up to approximately ⅔ of its length or width.
11 . The tissue filler of claim 10 , wherein the tissue filler is capable of returning to its original dimensions after release of compression.
12 . The tissue filler of claim 1 , wherein the acellular tissue matrix has a stable three-dimensional structure.
13 . The tissue filler of claim 1 , wherein the acellular tissue matrix comprises a dermal matrix.
14 . The tissue filler of claim 13 , wherein the acellular tissue matrix is derived from skin.
15 . The tissue filler of claim 13 , wherein the acellular tissue matrix is derived from dermis.
16 . The tissue filler of claim 1 , wherein the acellular tissue matrix is derived from at least one of lung, liver, bladder, muscle, and fat tissue.
17 . The tissue filler of claim 1 , wherein the acellular tissue matrix is derived from porcine tissue.
18 . The tissue filler of claim 1 , wherein the acellular tissue matrix comprises an adipose matrix.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.